Table 3. Outcomes based on network meta-analysis.
| Study outcome | No. of Studies compared | ECU vs HD | ECV vs HD | ECV vs ECU | |
| Relative risk (95 % CI) | I 2 | ||||
| Overall PDR | 9 | 1.25 (1.10–1.43) 1 | 1.14 (1.02–1.29) 1 | 0.92 (0.77–1.09) | 70.9 % |
| PDR 2 | 3 | 1.08 (0.99–1.17) | 1.01 (0.91–1.12) | 0.94 (0.82–1.07) | 0 % |
| PDR 3 | 6 | 1.35 (1.20–1.52) 1 | 1.21 (1.10–1.33) 1 | 0.90 (0.77–1.04) | 34.5 % |
| PDR 4 | 5 | 1.14 (1.01–1.29) 1 | 1.06 (0.96–1.18) | 0.93 (0.80–1.09) | 47.8 % |
| PDR 5 | 4 | 1.40 (1.20–1.63) 1 | 1.29 (1.13–1.47) 1 | 0.92 (0.75–1.13) | 23.7 % |
| Overall ADR | 12 | 1.22 (1.06–1.40) 1 | 1.12 (0.98–1.29) | 0.92 (0.76–1.12) | 69.2 % |
| ADR 2 | 5 | 1.07 (0.96–1.19) | 1.00 (0.88–1.13) | 0.93 (0.79–1.10) | 22.8 % |
| ADR 3 | 7 | 1.37 (1.16–1.61) 1 | 1.22 (1.07–1.42) 1 | 0.90 (0.72–1.12) | 45.3 % |
| ADR 4 | 7 | 1.16 (0.99–1.34) | 1.05 (0.91–1.20) | 0.90 (0.74–1.11) | 63.0 % |
| ADR 5 | 5 | 1.33 (1.06–1.67) 1 | 1.31 (1.05–1.64) 1 | 0.99 (0.72–1.36) | 42.5 % |
| AADR | 4 | 1.09 (0.77–1.53) | 1.08 (0.79–1.46) | 0.99 (0.63–1.58) | 38.1 % |
| SADR | 3 | 0.90 (0.58–1.41) | 1.87 (1.13–3.11) 1 | 2.07 (1.06–4.06) 1 | 0 % |
| NDR | 3 | 0.72 (0.19–2.67) | 1.34 (0.71–2.55) | 1.87 (0.44–8.02) | 52.1 % |
| CIR | 7 | 1.00 (0.99–1.01) | 1.00 (0.99–1.01) | 1.00 (0.99–1.01) | 0 % |
| Mean difference (95 % CI) | |||||
| Overall MPP | 6 | 0.53 (0.39–0.66) 1 | -0.13 (-0.30–0.05) | -0.65 (-0.87–– 0.43) 1 | 0 % |
| Overall MAP | 9 | 0.46 (0.13–0.79) 1 | 0.12 (-0.21–0.46) | -0.34 (-0.81–0.13) | 92.5 % |
AADR, advanced adenoma detection rate; ADR, adenoma detection rate; CI, confidence interval; CIR, cecal intubation rate; ECU, first-generation Endocuff colonoscopy; ECV, Endocuff Vision colonoscopy; HD, high-definition colonoscopy; MAP, mean adenoma per procedure; MPP, mean polyp per procedure; NDR, neoplasia detection rate; PDR, polyp detection rate; SADR, serrated adenoma detection rate.
1
P < 0.05 for the study estimate
2
Denotes studies with control ADR > 40 %
3
Denotes studies with control ADR ≤ 40 %
4
Denotes studies with control ADR > 30 %
5
Denotes studies with control ADR ≤ 30 %